Animace načítání

Stránka se připravuje...


Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

Právní předpis byl sestaven k datu 26.02.2026.

Zobrazené znění právního předpisu je účinné od 28.01.2025.


Sdělení Ministerstva zahraničních věcí, kterým se mění a doplňují sdělení Ministerstva zahraničních věcí č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

19/2025 Sb.
 

Sdělení

INFORMACE

19

XXXXXXX

Xxxxxxxxxxxx zahraničních xxxx,

xxxxxx xx xxxx x xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
&xxxx;

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx sděluje, xx xxx 1. xxxxx 2023 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx nového xxxxx Xxxxxxx X - Xxxxxx zakázaných xxxxx x xxxxx xxxxxxx xxx rok 2024 - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx úmluvy xxxxx xxxxxxx xx xxxxxx.

X xxxxx xxxxxx Přílohy X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxx listinu x xxxxxxx změn Přílohy X Českou republikou.

Nové xxxxx Xxxxxxx X xxxxxxxxx v platnost x souladu x článkem 34 xxxx. 3 Xxxxxx dne 1. xxxxx 2024, xxx Xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx xxx 18. června 2024 x nahradilo Xxxxxxx X pro xxx 2023, xxxxxxx xx 1. xxxxx 2023, xxxxx xxxxxxxxx x xxxxxxxx pro Xxxxxx xxxxxxxxx xxx 22. xxxxxx 2023 x xxxx vyhlášena xxx č. 32/2023 Sb. m. s.

Xxxxxxxx xxxxx Xxxxxxx X pro xxx 2024 a její xxxxxxx xx xxxxxxx xxxxxx xx vyhlašují xxxxxxxx.
&xxxx;

Xxxxxxx:

x x. XXXx. Xxxxxx, Xx.X., LL.M., x. r.

vrchní xxxxxxx xxxxx xxxxxx x xxxxxxxxxx
&xxxx;

Xxxxxxx č. 1

Překlad xxxxxxxxxxx smlouvy xx xxxxxxx jazyka

Úvod

Seznam xxxxxxxxxx xxxxx x metod xxxxxxx xx xxxxxxx Xxxxxxxxxxx xxxxxxxx x xxxxx Světového antidopingového xxxxxxxx.

Xxxxxx xx xxxxxxxxxx xxxxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx zprostředkovaném Xxxxxxxx antidopingovou agenturou (XXXX). Seznam xx xxxxxx xx 1. xxxxx 2024.

Xxxxxxxxx xxxx Xxxxxxx zakázaných látek x xxxxx xxxx xxxxxxxxx WADA x xxxx xxxxxxxxxx x xxxxxxxxxx a xxxxxxxxxxxxx. X xxxxxxx jakýchkoliv xxxxxxxxxxxxx xxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxx xxxxxxxxx xxxxx v xxxxxxxxxx.

Xxxx xxxx xxxxxxx xxxxxxx pojmy používané x xxxxx Xxxxxxx xxxxxxxxxx látek x xxxxx.

Xxxxxxxx Xxx soutěži

Pokud XXXX xxx xxxx xxxxx xxxxxxxxxxx jiné xxxxxx, je xxxxxx Xxx xxxxxxx x xxxxxx xxxxxxx xxxxxxxxxxx xxxxx xxxx xxxxxxx (xx 23:59 xxxxx) x xxx xxxxxxxxxxxxx Xxxxxxx, xxxxx xx xx Xxxxxxxxx xxxxxxxxx, xx xx konce Xxxxxxx x xxxxxxx xxxxxx Xxxxxx.

Xxxxxxxx xxxxx

Xx xxxxxxx, že xxxx xxxxx xxxx metoda xx zakázána Xxx xxxxxxx x Xxxx xxxxxx, xxx je xxxxxxxxxx x Xxxxxx.

Xxxxxxxxxx x Xxxxxxxxxxxx

Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx Xxxxxx „xxx xxxxx xxxxxxxx xxxxxx 10 xxxxx všechny Zakázané xxxxx Specifickými xxxxxxx, x xxxxxxxx xxxx xxxxxxxxxx x Seznamu xxxxxxxxxx látek a xxxxx dopingu. Xxxxx Xxxxxxxx xxxxxx xxxxxx Xxxxxxxxxxx metodou, xxxxx xxxx x Xxxxxxx xxxxxxxxx označena xxxx Xxxxxxxxxx metoda.“ Xxxxx xxxxxxxxx x článku „Xxxxxxxxxx xxxxx x Xxxxxxxxxx xxxxxx xxxxxxx x xxxxxx 4.2.2 xx neměly xxx xxxxxx xxxxxxxx xxxxxxxxxx xx méně xxxxxxxx xxxx méně xxxxxxxxxx xxx xxxx xxxxxxxxx xxxxx xxxx xxxxxx. Xxx xxxxx o xxxxx x xxxxxx, xxxxx Xxxxxxxxx xxxxxxxxxxxxx xxxx xxxx xxxxxx x xxxxxx účelu xxx xx xxxxxxxx xxxxxxxxxxx výkonu.“

Návykové látky

Podle xxxxxx 4.2.3 Xxxxxx xxxx Xxxxxxxx látky xxxxxxxxxx xxxx xxxxx, xxxxx jsou xxxx xxxxxx označeny x xxxxxx xxxxxx častého xxxxxxxxxx ve xxxxxxxxxxx xxxx rámec sportu. Xxxx Návykové xxxxx xxxx xxxxxxxxxx xxxx xxxxx: xxxxxx, xxxxxxxxx (xxxxxx), methylendioxymetamfetamin (MDMA/„extáze“), xxxxxxxxxxxxxxxxxxx (THC).

S0 XXXXXXXXXXX XXXXX

XXXXXXXX STÁLE (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx zakázané xxxxx x této xxxxx xxxx Specifické xxxxx.

Xxxxxxxxx xxxxxxxxxxxxxx xxxxx, xx xxxxxx xx nevztahuje xxxxx x následujících xxxxxx Xxxxxxx x xxxxx xxxx x xxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxx xxxxxxx xxxxxxx u xxxx (xxxx. xxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx nebo xxxxxxx xxxxx xxx xxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxx xxx veterinární xxxxxxx), xx zakázána xxxxx.

Xxxx xxxxx xxxxxxxx mnoho xxxxxxx xxxxx, xxxx xxxx XXX-157, 2,4-xxxxxxxxxxxx (XXX) x xxxxxxxxxx xxxxxxxxx (např. Xxxxxxxxxxx x Tirasemtiv).

S1 ANABOLICKÉ XXXXX

XXXXXXXX STÁLE (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Nespecifické látky.

Anabolické xxxxx xxxx xxxxxxxx.

X1.1. XXXXXXXXXX ANDROGENNÍ XXXXXXXX (XXX)

Xxx exogenním podání, xxxx jiné xxxxxx:

1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3ß, 17ß-xxxx)

&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;

&xxxx;•&xxxx;

xxxxxxxxxx

1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3,17-xxxx)

&xxxx;•

xxxxxxxxx (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx)

1-xxxxxxxxxxx (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx)

&xxxx;•

xxxxxxxxx

1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx)

&xxxx;•

xxxxxxxxxx

1-xxxxxxxxxxx (17ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-3-xx)

&xxxx;•

xxxxxxxxxx

4-xxxxxxxxxxxxxx (xxxxxxx-4-xx-3ß, 17ß-xxxx)

&xxxx;•

xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxxx-1,4-xxxx-3-xx)

4-xxxxxxxxxxxxxxxxxx(4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx)

&xxxx;•

xxxxxxxxx

5-xxxxxxxxxxxxxx (androst-5-en-3,17-dion)

 •

metandriol

7ɑ-hydroxy-DHEA

 •

metasteron (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx)

7ß-xxxxxxx-XXXX

&xxxx;•

xxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxx-5ɑ-xxxxxxx-1-xx-3-xx)

7-xxxx-XXXX

&xxxx;•

xxxxxxxxxxxxxx

11ß-xxxxx-19-xxxxxxxxxxxxxx

&xxxx;•

xxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx)

17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx)

&xxxx;•

xxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxx-4-xx-3-xx)

19-xxxxxxxxxxxxxxxxx (estr-4-en-3,17-diol)

 •

metyltestosteron

19-norandrostenedion (xxxx-4-xx-3,17-xxxx)

&xxxx;•

xxxxxxxxxx (xxxxxxxxxxxxxx, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)

Xxxxxxx-4-xx-3,11,17-xxxxx(11-xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx)

&xxxx;•

xxxxxxxxx

xxxxxxxxxxxxx (5ɑ-xxxxxxxxxxxxxxxxxx, 17ß-hydroxy-5ɑ-androstan-3-on)

 •

nandrolon (19-xxxxxxxxxxxxxx)

xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx)

&xxxx;•

xxxxxxxxxx

xxxxxxxxxxxxxx (androst-4-en-3,17-dion)

 •

norklostebol (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx)

xxxxxxxxxx

&xxxx;•

xxxxxxxxxxxxx

xxxxxxxx

&xxxx;•

xxxxxxxx

xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx)

&xxxx;•

xxxxxxxxxx

xxxxxxxxxx

&xxxx;•

xxxxxxxxxxx

xxxxxxxxx

&xxxx;•

xxxxxxxxxx

xxxxxxx ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx)

&xxxx;•

xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA, 3β-xxxxxxxxxxxxxx-5-xx-17-xx)

xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxx-1,4-xxxx-3-xx)

&xxxx;•

xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx)

xxxxxxxxxxxxxxxxxxxxxx (17ɑ-methyl-5ɑ-androst-2-en-17ß-ol x 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- xx)

&xxxx;•

xxxxxxxxx

xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx)

&xxxx;•

xxxxxxxxxx

xxxxxxxxxxx

&xxxx;•

xxxxxxxxx

xxxxxxxxxxxxxx (3β-xxxxxxx-5α-xxxxxxxxx-17-xx)

&xxxx;•

xxxxxxxxxxx

xxx-xxxxxxxxxxxxxxxxxx (17β-xxxxxxx-5β-xxxxxxxxx-3-xx)

&xxxx;•

xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx)

xxxxxxxxxxxxxx

&xxxx;•

xxxxxxx

xxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx)

&xxxx;•

xxxxxxxxx (17β-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)

xxxxxxxxxxxxxx

&xxxx;•

xxxxxxxxx (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, XXXX)

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

S1.2. XXXXXXX ANABOLICKÉ XXXXX

Xxxx xxxx včetně:

Clenbuterol, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx [XXXX, xxxx. andarin, xxxxxxxxx (xxxxxxx), XXX-4033 (xxxxxxxxx), XXX140, X-23 x XX-11], zeranol x xxxxxxxxxx.

X2 XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX, XXXXXXXX XXXXX X XXXXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX)

Xxxxxxx xxxxxxxx látky x xxxx třídě xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx látky x další látky x xxxxxxxx chemickou xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx.

X2.1. XXXXXXXXXXXXX (EPO) X XXXXX XXXXXXXXXXX XXXXXXXXXXX

Xxxx jiné xxxxxx:

X2.1.1 Xxxxxxxx erytropoetinových receptorů, xxxx. darbepoetiny (dEPO); xxxxxxxxxxxxx (XXX); xxxxxxxxxx xxxxxxxx na XXX, [xxxx. XXX-Xx, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)]; EPO- xxxxxxxxx prostředky x xxxxxx xxxxxxxxxx, např. XXXX-530, peginesatid.

S2.1.2 Xxxxxxxxx xxxxxxxxxx hypoxii xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxx; xxxxxxxxxxx (XXX1278863); XXX2; xxxxxxxxxx (XXX 85-3934); xxxxxxxxxx (FG-4592); xxxxxxxxxx (XXX-6548); xxxxx.

X2.1.3 Xxxxxxxxxx XXXX, xxxx. X-11706.

X2.1.4 Xxxxxxxxxx signalizace xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxx (XXX-β), xxxx. xxxxxxxxxxxx; sotatercept.

S2.1.5 Xxxxxxxx xxxxxxxxx xxxxxxxxx receptoru, xxxx. asialo EPO; xxxxxxxxxxxxx XXX (XXXX).

X2.2. XXXXXXXXX XXXXXXX A XXXXXX XXXXXXXXXX XXXXXXX

X2.2.1 Xxxxxxx xxxxxxxxxxx xxxxxxxxxxx x mužů, mimo xxxx xxxxxx:

• xxxxxxxx xxxxxxxxxxxx (XX),

• xxxxxxxxxxxx xxxxxx (LH),

• hormon xxxxxxxxxx xxxxxxxxxxxx (XxXX, xxxxxxxxxxx) a xxxx xxxxxxxxxxx analogy (xxxx. xxxxxxxxx, xxxxxxxxxx, goserelin, xxxxxxxxx, xxxxxxxxxxx, nafarelin x xxxxxxxxxxx),

&xxxx;• kisspeptin x jeho xxxxxxxxxxx xxxxxxx.

X2.2.2 Xxxxxxxxxxxxxx a xxxxxx xxxxxxxxxx faktory, xxxx. kortikorelin a xxxxxxxxxxxxx.

X2.2.3 Xxxxxxx xxxxxx (XX), xxxx xxxxxxx x xxxxxxxxx, xxxx xxxx xxxxxx:

• xxxxxxx xxxxxxxxx hormonu, např. xxxxxxxxxxxxxxxxx, xxxxxxxxxxx a xxxxxxxxxx,

• xxxxxxxxx xxxxxxxxx xxxxxxx, xxxx. AOD-9604 x xXX 176–191.

X2.2.4 Xxxxxxx xxxxxxxxxx xxxxxxx xxxxxx, mimo jiné xxxxxx:

• xxxxxx uvolňující xxxxxxx xxxxxx (XXXX) x xxxx xxxxxxx, xxxx. CJC-1293, XXX-1295, xxxxxxxxxx x tesamorelin,

• xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX) x xxxxxx xxxxxxxx [xxxx. xxxxxxxxxx, xxxxxxxxxxxx, ibutamoren (XX-677), xxxxxxxxxx, xxxxxxxxxxx (ghrelin), xxxxxxxxxxx a xxxxxxxxxxx],

• xxxxxxx xxxxxxxxxx XX (XXXX) [xxxx. xxxxxxxxxxxx, xxxxxxxxxx (hexarelin), XXXX-1, XXXX-2 (xxxxxxxxxxx), XXXX-3, XXXX-4, XXXX-5 a XXXX-6].

X2.3. RŮSTOVÉ XXXXXXX X XXXXXXXXXX RŮSTOVÝCH XXXXXXX

Xxxx jiné včetně:

• xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• xxxxxxxxxxxx růstový xxxxxx (XXX)

• xxxxxxx xxxxxx 1 xxxxxxx xxxxxxxx (XXX-1, mecasermin) x xxxx xxxxxxx

• xxxxxxxxxx xxxxxxx faktory (XXX)

• xxxxxxx xxxxxx xxxxxxxx x krevních xxxxxxxx (XXXX)

• xxxxxxxx-β4 x xxxx xxxxxxxx, xxxx. XX-500

• xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (VEGF)

a xxxxx xxxxxxx xxxxxxx xxxx modulátory růstových xxxxxxx xxxxxxxxxxx xxxxxxx/xxxxxxxxx xxxxxxxx ve xxxxxxx, xxxxxxxx xxxx xxxxxx, xxxxxxxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx kapacitu xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.

X3 XXXX-2 XXXXXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX SOUTĚŽ)

Všechny xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx látky.

Všichni xxxxxxxxxx x xxxxxxxxxxxx xxxx-2 xxxxxxxx xxxxxx xxxxx xxxxxxxxx izomerů xxxx xxxxxxxx.

Xxxx jiné včetně:

arformoterol

indakaterol

reproterol

tretoquinol (xxxxxxxxxxxxx)

xxxxxxxxx

xxxxxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

XXXXXXX

• Inhalační xxxxxxxxxx: xxxxxxxxx 1600 mikrogramů xx 24 hodin x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 600 mikrogramů xxxxx 8 xxxxx xx xxxxxxxxx dávce;

• xxxxxxxxx formoterol: xxxxxxxxx xxxxxx dávka 54 xxxxxxxxxx xx 24 xxxxx;

• xxxxxxxxx salmeterol: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 25 xxxxxxxxxx xx 24 xxxxx.

XXXXXXXX

Xxxxxxxxxx salbutamolu x moči v xxxxxxxx vyšším xxx 1000 ng/ml xxxx xxxxxxxxxxx x množství xxxxxx xxx 40 xx/xx neodpovídá xxxxxxxxxxxxxx xxxxxxx látky x xxxx považována za Xxxxxxxxx laboratorní xxxxx (XXX), pokud Sportovec xxxxxxxxx xxxxxxxxxxxxx farmakokinetickou xxxxxx, xx xxxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxxxxxxx dávky (xxxxxxxxx) xx xx výše xxxxxxx xxxxxxxxx xxxxx.

X4 XXXXXXXXX A XXXXXXXXXXX XXXXXXXXXX

XXXXXXXX STÁLE (XXX XXXXXXX X MIMO XXXXXX)

Xxxxxxxx látky xx xxxxxxx S4.1 a X4.2 jsou Xxxxxxxxxx xxxxx.

Xxxxx xxxxxxxx xx xxxx X4.3 x X4.4 xxxx Nespecifické xxxxx.

Xxxxxxxxxxx xxxxxxxxx a xxxxxxxxxxx modulátory jsou xxxxxxxx.

X4.1. INHIBITORY XXXXXXXX

Xxxx xxxx včetně:

2-androstenol (5ɑ-androst-2-en-17-ol)

androsta-1,4,6-trien-3,17-dion (xxxxxxxxxxxxxxxxx)

2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx)

xxxxxxxx-3,5-xxxx-7,17-xxxx (xxxxxxxxx)

3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)

xxxxxxxxx

3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)

xxxxxxxxx

4-xxxxxxxxx-3,6,17 xxxxx (6-xxx)

xxxxxxxx

xxxxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

X4.2. XXXXXXXXXXXXXX XXXXX [XXXXXXXXXXXXX X SELEKTIVNÍ XXXXXXXXXX ESTROGENOVÝCH XXXXXXXXX (XXXXX)]

Xxxx xxxx včetně:

arformoterol

indakaterol

reproterol

tretoquinol (xxxxxxxxxxxxx)

xxxxxxxxx

xxxxxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

X4.3. XXXXX XXXXXXXXXXX XXXXXXXX XXXXXXXXX XXXXXXXX XXX

Xxxx xxxx včetně:

protilátky xxxxxxxxxxxxxx xxxxxxx A

inhibitory xxxxxxxxxx, např.:

konkurenty xxxxxxxxx xxxxxxxx XXX, např.:

- xxxxx xxxxxxxxx xxxx xxxxxx xxxxxxx xxxxxxxxxx

- xxxxxxx receptory xxxxxxxx (xxxx. ACE-031)

- xxxxxxxx xxxxxx xxxxxxxxx (xxxx. xxxxxxxxxxx, xxxxxxxxx xxxxxxxxxx)

xxxxxxxxxx xxxxx xxxxxxxxx aktivinu XXX (xxxx. xxxxxxxxxx)

- xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxxx (např. xxxxxxxxxxx, xxxxxxx xxxxx, xxxxxxxxxxxxx, xxxxxxxxxx)

X4.4. XXXXXXXXXXX XXXXXXXXXX

X4.4.1 aktivátory XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), např. XXXXX, xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx (PPARδ), např. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (trifluormetyl)fenyl)thiazol-5-yl)metylthio)fenoxy) xxxxxxxx xxxxxx (GW1516, XX501516) x agonisté Xxx-xxxɑ , xxxx. XX9009, XX9011

X4.4.2 xxxxxxxx x xxxxxxxx xxxxxxxx

X4.4.3 xxxxxxxxx

X4.4.4 xxxxxxxxxxxx

X5 DIURETIKA X XXXXXXXXX XXXXX

XXXXXXXX STÁLE (XXX SOUTĚŽI I XXXX SOUTĚŽ)

Všechny zakázané xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx diuretika x xxxxxxxxx xxxxx, xxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx. x- x x-, xxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

•&xxxx; Xxxxxxxxx, xxxx xxxx.:

xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxx; xxxxxxxx; chlortalidon; xxxxxxxx xxxxxxxxxx; xxxxxxxxx; xxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxxx; xxxxxxxx, např. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx x xxxxxxxxxxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx;

• Xxxxxxx, xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx;

• Plazmatické xxxxxxxxx xxxxxxxx xxxxxxxxxxxx, xxxx.:

xxxxxxx, xxxxxxx, xxxxxxxxxxx xxxxx, xxxxxxxx;

• Xxxxxxxxxxx;

• Xxxxxxxxxx;

x xxxxx xxxxx x xxxxxxxx chemickou strukturou xxxx xxxxxxxxx biologickými xxxxxx.

XXXXXXX

• xxxxxxxxxxx; pamabrom; x xxxxxxx xxxxxxxxxxxxxx xxxxxxxx inhibitorů xxxxxxxxxxxxxx (xxxx. xxxxxxxxxx, xxxxxxxxxxx);

• xxxxxxx xxxxxx xxxxxxxxxxx x xxxxx xxxxxxxxx.

XXXXXXXX

Xxxxx xxxxxxxxxxx množství látky xx xxxxxxxxxx xxxxxxxx xxxxxxx: x xxxxxxxxxxx, xxxxxxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxxxxxx x xxxxxxxxxxxxxx xx Xxxxxx Sportovce xxxxxxxx xxxx xxxxxxxx Xxx Soutěži ve xxxxxxx x xxxxxxxxxx xxxx jinou xxxxxxxxx xxxxxx (xxxxx xxxxxxxxx xxxxxx podání inhibitoru xxxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx), xxxx xxxxxxxxx xx Pozitivní xxxxxxxxxxx xxxxx (AAF), xxxxx Xxxxxxxxx nemá xxxxxxxxxx Xxxxxxxxxxxxx výjimku (XX) na xxxx xxxxx navíc x xx, xxxxx xxx xxxx xxxxxxx xx xxxxxxxxxx xxxx jinou xxxxxxxxx látku.

ZAKÁZANÉ METODY

ZAKÁZANÉ XXXXX (PŘI XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx metody x xxxx xxxxx xxxx Xxxxxxxxxxxx x výjimkou xxxxx x M2.2, xxx xxxx Xxxxxxxxxx xxxxxx.

X1. MANIPULACE S XXXX A XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

X1.1. Xxxxxx xxxx opětovné xxxxxxxx jakéhokoliv xxxxxxxx xxxxxxxxx, xxxxxxxxx (homologní) xxxx xxxxxxxxxxx xxxx xxxx produktů x xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx s xxxxxxxx xxxxxxxx xxxxxx xxxx xxxxxx xxxxxx Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxxxx xxxxxxxxx xxxxxx.

X1.2. Umělé zvyšování xxxxxx, xxxxxxx xxxx xxxxxxx kyslíku.

Mimo xxxx xxxxxx:

Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (XXX13); xxxxxxxxx a xxxxxxxxxxxx xxxxxxxxxxxxx produkty, xxxx. xxxxxx náhražky xx xxxx xxxxxxxxxxx x xxxxxxxxxxxxxxxx hemoglobinové xxxxxxxx, x xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxx.

X1.3. Xxxxxxxxx xxxxx intravaskulární xxxxxxxxxx x xxxx xxxx x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.

X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X2.1. Xxxxxxxxx nebo Xxxxx x podvod xx xxxxxx porušit xxxxxxxxx a xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx kontrole.

Mimo jiné xxxxxx:

Xxxxxx x/xxxx xxxxxx Xxxxxx, xxxx. xxxxxxxx xxxxxxx xx Xxxxxx.

X2.2. Xxxxxxxxxx infuze a/nebo xxxxxxx více než xxxxxx 100 xx xx 12 hodin xxxxx xxxxxx legitimně xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxxx, xxxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx.

X3. GENOVÝ X XXXXXXX DOPING

Z xxxxxx xxxxxxxxxxxxxxx zvýšení xxxxxxxxxxx xxxxxx je xxxxxxxx následující:

M3.1. Xxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxx, xxxxx xxxxx xxxxxx xxxxxxxx xxxxxx a/nebo xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxx. Xx xxxx jiné xxxxxxxx xxxxxxxxxxx úprav xxxx, xxxxxxxxx xxxx x xxxxxxxxxxx přenosů xxxx.

X3.2. Použití xxxxxxxxxx xxxx xxxxxxxxx modifikovaných xxxxx.

X6 XXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Specifické látky x výjimkou látek xxxxxxxxx x X6.X, xxx xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxx xxxxx v xxxx xxxxx: xxxxxx x metylendioxymetamfetamin (XXXX/„xxxxxx“)

Xxxxxxx xxxxxxxxxxx, včetně xxxxx xxxxxxxxx xxxxxxx, např. x- x l-, xxxx zakázána.

Stimulancia xxxxxxxx:

X6.X: XXXXXXXXXXXX STIMULANCIA

adrafinil

fonturacetam [4-xxxxxxxxxxxxxx (xxxxxxxx)]

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxx

xxxxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

xxxxxxxx

xxxxxxxxxxxxxxx

xxxxxxxxxxxx(x-)

xxxxxxxxx

x-xxxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxx

xxxxxx

xxxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxx

xxxxxxxx

xxxxxxxxxx

xxxxxxxxx

xxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxxx

Xxxxxxxxx, který není xxxxxxxx xxxxxx x xxxxx oddíle, je Xxxxxxxxxxx látkou.

S6.B: SPECIFICKÁ XXXXXXXXXXX

Xxxx xxxx včetně:

2-fenylpropan-1-amin (ß-xxxxxxxxxxxxxx-xxxx, BMPEA)

famprofazon

oktopamin

3-metylhexan-2-amin (1,2-dimetylpentylamin)

fenbutrazát

oxilofrin (xxxxxxxxxxxxx)

4-xxxxxxxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxx

4-xxxxxxxxxx-2-xxxx (1,3-dimetylamylamin, 1,3 XXXX, xxxxxxxxxxxxxx)

xxxxxxxxxx

xxxxxxxxxxx

4-xxxxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxxxx)

xxxxxxxxxx (xxxxxxxxx)

xxxxxxxxxxx a jeho xxxxxxxx

5-xxxxxxxxxx-2-xxxx (1,4-xxxxxxxxxxxxxxx, 1,4-dimetylpentylamin, 1,4-XXXX)

xxxxxxxxxxxxxxxx (parahydroxyamfetamin)

fenmetrazin

benzfetamin

isomethepten

fenprometamin

katin1)

levmetamfetamin

propylhexedrin

katinon x xxxx xxxxxxx, xxxx. xxxxxxxx, xxxxxxxx x ɑ-xxxxxxxxxxxxxxxxxxxxxx

xxxxxxxxxxxx

xxxxxxxxxxxxx2)

xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx)

xxxxxxxxxxxxxxxxxxxxxxxx

xxxxxxxxx

xxxxxxx3)

xxxxxxxxxxxx3)

xxxxxxxxxx

xxxxxxxxx (xxxxxxxxx)4)

xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- xx)xxxxxx]

xxxxxxxxxxxx

xxxxxxxx

xxxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx)

xxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxxxxx

xxxxxxxxx

xxxxxxxx (1,5-xxxxxxxxxxxxxxxx)

x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx

XXXXXXX

• xxxxxxxx;

• xxxxxxxx xxxxxxxxxxx x xxxxxxx xxxxxx xxxxxxx, xxxxxxx, xxxxxx nebo xxxxxx xxxxxxx (xxxx. xxxxxxxxxx, xxxxxxxxxx, fenoxazolin, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxx) x xxxxxxxxxxx xxxxxxxx xx Xxxxxxxxxxxxxx programu 20245).

X7 NARKOTIKA

ZAKÁZANÉ XXX XXXXXXX

Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxx látky.

Návykové xxxxx x xxxx xxxxx: xxxxxxxxx (heroin)

Následující xxxxxxxxx, xxxxxx jejich xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx. x- x x, jsou xxxxxxxx.

xxxxxxxxxxx

xxxxxxxx a jeho xxxxxxxx

xxxxxx

xxxxxxxxxx

xxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

xxxxxxx

xxxxxxxxx (xxxxxx)

xxxxxxx

xxxxxxxx

xxxxxxxx

xxxxxxxxx

X8 KANABINOIDY

ZAKÁZANÉ XXX XXXXXXX

Xxxxxxx zakázané xxxxx v xxxx xxxxx xxxx Specifické xxxxx. Xxxxxxxx látky x xxxx sekci: xxxxxxxxxxxxxxxxxxx (XXX)

Xxxxxxx xxxxxxxx x syntetické xxxxxxxxxxx xxxx zakázané, např.

• x konopí (xxxxx, xxxxxxxxx) x konopných xxxxxxxxxx

• xxxxxxxx x xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx (XXX)

• xxxxxxxxxx kanabinoidy napodobující xxxxxx THC

VÝJIMKY

• xxxxxxxxxx

X9 XXXXXXXXXXXXXXX

XXXXXXXX XXX SOUTĚŽI

Všechny xxxxxxxx látky v xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxxxxxxxx xxxx xxxxxxxx, pokud xxxx xxxxxxxx xxxxxxxxxx xxxxxxxx, xxxxxxxxx [xxxxxx xxxxxxxxxx (např. bukální, xxxxxxxxxx, xxxxxxxxxxxx)] nebo xxxxxxxx cestou.

Mimo xxxx xxxxxx:

xxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxxx acetonid

kortizon

hydrokortizon

deflazakort

metylprednisolon

POZNÁMKA

• Jiné xxxxxxx xxxxxx (xxxxxx xxxxxxxxxxx a xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, dermálního, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, ušního a xxxxxxxxxxxx) nejsou xxxxxxxx, xxxxx xx používají x xxxxx xxxxxxxx xxxxxxxxxxxx xxxxx a xxxxxxxxxxxxxx xxxxxxxx.

X1 XXXX-XXXXXXXXX

XXXXXXXX X URČITÝCH XXXXXXXX

Xxxxxxx xxxxxxxx látky v xxxx třídě xxxx Xxxxxxxxxx xxxxx.

Xxxx-xxxxxxxxx xxxx xxxxxxxx pouze x xxxxxxxxxxxxx xxxxxxxx Xxx Xxxxxxx x xxx xx xx xxxxxxxx xxxxxxxx (*) x Xxxx xxxxxx.

• xxxxxxxxxxx (XX)*

• lyžování/snowboarding (XXX) – skoky xx xxxxxx, xxxxxxxxxxx skoky / U-rampa a xxxxxxxxx X-xxxxx / xxx xxx

• automobilový xxxxx (XXX)

• xxxxxxxx xxxxxx (CMAS)* x xxxxxxxxxxxx xxxxxxx xxxxxxxx, xxxx xxxxxxxx x xxxxxxx xx xxxx

• xxxxxxxx (xxxxxxx disciplíny) (XXXX)

• xxxxx (XXX)

• xxxx (XXX)

• xxxxxxxx (XXX)

• střelba (XXXX, XXX)*

* xxxxxxxx xxxx Xxxx xxxxxx

Xxxx xxxx xxxxxx:

xxxxxxxxxx

xxxxxxx

xxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxx

xxxxxxxxxxxx

xxxxxxxx

xxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxx

xxxxxxx

xxxxxxx

xxxxxxxxxx

xxxxxxx

xxxxxxxxx

xxxxxxx

Xxxxxxx č. 2

Xxxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxx xxxxxx
&xxxx;

1) xxxxx (x-xxxxxxxxxxxxxxxx) x xxxx x-xxxxxx: je xxxxxxxx xxxxx xxx koncentraci x xxxx vyšší xxx 5 mikrogramů x 1 ml.

2) xxxxxxxxxxxxx: xxxxxxxx pouze xxx xxxxxxxxxxx v xxxx xxxxx xxx 150 xxxxxxxxxx x 1 xx.

3) efedrin x xxxxxxxxxxxx: xxxxxxxx xxx koncentraci v xxxx xxxxx než 10 xxxxxxxxxx x 1 xx.

4) xxxxxxxxx (xxxxxxxxx): není zakázáno xxxxxxx xxxxxxxx, xxxx. xxxxx, xxxx, xxxx xxxxxxxx podávání x xxxxxxxxx anestetiky.

5) xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx x xxxxxxxx: xxxx xxxxx xxxx zahrnuté do Xxxxxxxxxxxxxx programu 2024 x nejsou xxxxxxxxxx xx Xxxxxxxx xxxxx.

Xxxxxxxxx

Xxxxxx xxxxxxx x. 19/2025 Sb. xxxxx xxxxxxxxx xxxx 28.1.2024.

Znění xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx předpisů x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx předpisu